In brief Progress
First proofs of principle for therapeutic in utero gene application and for the induction of tolerance to lifelong expression of a transgenic human protein have been provided in mouse models of human genetic disease. Minimally invasive ultrasound guided gene delivery procedures applicable to the human fetus have been developed in large animal models. The possible adverse effects of prenatal gene delivery, including germ-line transfer of transgenic DNA sequences, developmental aberrations caused by expression of transgenic proteins and vector-induced oncogenesis, need to be carefully assessed before clinical application can be considered. The choice of disease for clinical application requires a high level of certainty that benefit will be provided and that the procedure will not cause additional harm as termination of pregnancy remains an option to deal with prenatally diagnosed genetic disease.
Introduction
The concept of fetal (prenatal or in utero) gene therapy is based on the aims of avoiding early-onset manifestation of life-threatening genetic conditions, achieving permanent correction of such diseases by stable transduction of relevant fetal progenitor cell populations and avoiding immune reactions against the therapeutic vector and transgene by induction of tolerance. Although fetal gene therapy will not replace postnatal gene therapy, it is essentially a preventive approach to the management of otherwise predominantly incurable diseases and would therefore -if successful and safe -be most effectively conducted in conjunction with prenatal screening programmes. 1 Maria Hatzoglou et al in Richard Hanson's laboratory were the first to apply a replication-incompetent retrovirus vector intraperitoneally to fetal rats in utero in 1990 and showed that it mediated expression of human growth factor. This was significantly more effective than when the same vector was administered to adult animals via the portal vein after partial hepatectomy. The following years saw a large number of in utero marker gene experiments using several vectors and different animal models, which demonstrated gene delivery to virtually all fetal tissues (for review see David et al 2 ). However, the first report of a curative gene therapy protocol in utero by prenatal injection of adenovirus into the amniotic fluid of CFTR knockout (KO) mice, by Larson et al in 1997, was substantially criticized in the literature at the time and has not been reproduced independently since then. The first widely accepted confirmation for the concept of fetal gene therapy has only recently been provided by the correction of several different disease phenotypes in relevant animal models. [3] [4] [5] [6] Since gene therapy for genetic diseases requires lifelong correction, a vector system with the capability of permanent transgene expression such as retro/ lentiviruses appears presently as the best choice. However, the recent occurrence of oncogenesis by such vectors (see below) indicates their present limitations. AAV integration is relatively low and it has the tendency to be maintained in an episomal state for a prolonged time. However, it tends to be lost quite considerably in rapidly dividing tissues although novel serotype AAV vectors with much higher efficiency may still be able to retain enough copies to provide a long-term therapeutic effect. Indications of a potential AAV oncogenesis in mice has been reported by Donsante et al. in 2001 and reaffirmed at the 2005 American Society of Gene Therapy conference (Embury et al Abstract 423). First-generation adenovirus is well known for its transient maintenance and expression. However, its broad tissue tropism and high infectability has made it an ideal pathfinder vector for studies on in utero gene delivery in different animals, and later generations of vector, in particular the helperdependent adenovirus vectors, are significantly less immunogenic and show long-lasting expression properties. As in postnatal gene therapy, further developments on vector safety and efficiency remain key issues for further progress.
First proofs of principle for therapeutic in utero gene application and for the induction of tolerance to lifelong expression of a transgenic human protein have been provided in mouse models of human genetic disease (Table 1) The first successful therapeutic application of gene transfer in utero was performed in 2003 by Seppen et al 3 by direct injection of a lentiviral vector expressing the human bilirubin UDP-glucuronyltransferase (UGT1A1) gene under control of the phosphoglycerate kinase promoter into the liver of Gunn rat fetuses. The Gunn rat is a model for the very rare autosomal recessive human condition Crigler Najjar disease Type I (CN l), caused by mutations in the gene encoding UGT1A1 on human chromosome 2. Toxic levels of bilirubin accumulate in the patient's blood leading to severe brain damage. Although the expression of human UGT1A1 in the livers of treated fetuses was too low to allow detection by Western blotting, a reduction in the levels of nonconjugated bilirubin of about 45% was demonstrated over a period of 1 year. In patients with CN I, such reduction would convert severe CN I disease to the milder CN II form. However, the absolute levels of unconjugated bilirubin observed in human CN I are substantially higher than those found in the Gunn rat and it is therefore not clear if the levels of transduction and expression of the transgenic protein achieved in the rat would be sufficient for a therapeutic effect in man. 7 The gene for RPE65 is located on human chromosome 1, and the protein functions in a cascade of molecular events involved in rhodopsin production. Although nearly complete normalization of the electro-retinogram (ERG) was only achieved in two of the 13 pups that survived to adulthood, more than 50% showed a therapeutic ERG change and 70% had an improved photoresponse sensitivity. The limited numbers are most likely due to technical difficulties of topical gene delivery to the retina. Interestingly, however, these experiments also showed that the effects on ERG after in utero injection, in many cases, surpassed the response after postnatal injection. It is also noteworthy that RPE65 expression could be observed after 5-6 months as the AVV vector is known to remain predominantly episomal, potentially resulting in significant loss of vector in the rapidly dividing fetal tissue. After the reported time of observation, however, the retinal epithelium is virtually nondividing and therefore any future loss would be due either to loss of retinal cells or vector shutdown.
Further successful in utero application of an AAV vector was reported by Rucker et al. 5 Intraperitoneal in utero application of an AAV-2 vector expressing the lysosomal enzyme acid alpha glucosidase (GAA) to fetuses of a mouse model of Pompe's disease restored the enzyme levels in the diaphragm of these animals and prevented glycogen accumulation in this muscle. This glycogen accumulation leads, in the untreated animals, to disruption of the contractile apparatus and in humans to neonatal death from respiratory insufficiency. Nearnormal contractile properties of the diaphragm were found up to 6 months after vector application.
Finally, Waddington et al 6 observed therapeutic levels of human factor IX of between 18 and 32% of normal values ( Figure 1 ) and permanent amelioration of the bleeding disorder in factor IX KO mice (a model for human haemophilia B). This was achieved by in utero administration of an HIV lentiviral vector via the fetal yolk sac vessels, a route that delivers a large proportion of the vector directly to the liver. The factor IX KO mice have no functional factor IX, and restoration of levels to 5% of normal corresponds in humans to a mild haemophiliac phenotype and 40% to phenotypic cure. Determination of factor IX blood levels allowed the monitoring of transgene expression in the individual treated animals over their lifetime. Animals were culled for molecular analysis between days 321 and 432 after gene delivery, without detection of any adverse effects. This long observation period also allowed repeated testing of antibody levels, with and without exogenous challenge. Importantly, no antibodies against the human protein were found even after adjuvant stimulation, whereas strong antibody responses were observed after the same challenge on haemophiliac mice not treated in utero. In liver biopsies, human factor IX expression was detected in groups of neighbouring cells suggesting clonal propagation of human factor IX-expressing fetal cells with progenitor function, similar to earlier observations with a b-galactosidase expression vector. 8 In an earlier experiment using an adenovirus vector, 14 we also observed tolerance against the human protein but not against the adenovirus vector. This is not unexpected as the fetus is only exposed to the viral proteins for a very short time.
Taken together, these four independent studies in different animal models, and using differing transgenes, have shown that prenatal gene delivery can provide early phenotypic correction, sufficient to reduce or avoid otherwise devastating effects of genetic diseases. They demonstrate long-term postnatal therapeutic protein production based on long-term transgene expression from the initially transduced cells and their progeny, and the study by Waddington et al 6 also demonstrates that tolerance to the transgenic protein can be induced by in utero expression.
Minimally invasive ultrasound-guided gene delivery procedures applicable to the human fetus have been developed in large animal models How closely do these proof-of-principle studies in mice bring us to the goal of human fetal gene therapy? Firstly, species differences need to be taken into account. Obviously, the huge size difference between mice and humans will dictate different approaches to vector delivery and require experimentation on larger animal models.
To accomplish this, in 1999 our team was the first to adopt minimally invasive ultrasound-guided methods, as already used in human fetal medicine, for gene delivery into the umbilical vein of sheep fetuses. Ultrasound guidance has also been used more recently for delivery to the amniotic cavity or for direct injection of the parenchyma of the liver and lung in primates by the teams of Larson and Tarantal, respectively. Primates are most likely the ultimate animal model that will have to be used for safety studies in immediate preparation for a clinical trial, but their breeding conditions and high costs make them prohibitory for routine use for the Fetal gene therapy C Coutelle et al development of novel techniques. Sheep are much easier to breed and maintain and are a well-established animal model of human fetal physiology with a consistent gestation period of about 145 days and predominantly singleton pregnancies. They also tolerate in utero manipulations and have anatomical features allowing interventions that are applicable to the human fetus. Further, they show important similarities to humans in the development of their immune system. Recently, our team has developed methods that allow access to most organ systems, and at gestational ages that have not yet been tried in humans, opening potential new fields of application in fetal medicine.
2,9-11 These studies have defined clear windows of feasibility for the different application routes as summarized in Table 2 .
For these procedures, maternal mortality is negligible and fetal mortality is between 10 and 15%. Over 90% of the fetal mortality was due to iatrogenic infection, usually with known commensals from the sheep fleece, and in only 20% was the cause procedure-related trauma. Exceptions are intracardiac application and umbilical vein injection at around DG (days of gestation) 55, which produce an unacceptably high procedure-related fetal mortality, while umbilical vein injection is achievable at DG 60 but is not sufficiently reliable until DG 70.
The relevant time windows for man for the different application routes still need to be established both with respect to technical feasibility and in relation to physiological development. Thus, for instance, the preimmune period for the sheep fetus is assumed to last up to days 60-65 of gestation but for the human fetus this still needs to be established, and may also require initial primate experiments.
Regulatory T-cells, involved in the maintenance of immune tolerance, have been detected as early as 13 weeks in the human fetus, whereas in mice these cells cannot be detected in the periphery until day 3 after birth. 12 In sheep, the first T-cells are observed in the fetal circulation by DG 50, although mature neutrophils can only be found from DG 120 onwards. Another specific difference between the mouse and human fetus, and indeed also between sheep and humans, is the placental structure. Six and three cell layers separate the fetal and maternal circulations in the ovine synepitheliochorial placenta and the murine haemotrichorial placenta, respectively. In contrast, only one layer of syncytial trophoblasts acts as the barrier between maternal blood and fetal capillaries in the haemomonochorial placenta of primates and the guinea-pig. This may be of importance in assessing the possible risk of vector spread from the fetus to the maternal body, 13 although the number of layers may not be the only factor determining placental permeability. We are, therefore, planning studies on vector spread in guinea-pigs, but ultimately primate studies may again be required.
The possible adverse effects of prenatal gene delivery, including germline transfer of the transgenic DNA sequences, developmental aberrations caused by expression of the transgenic proteins and vectorinduced oncogenesis, need to be carefully assessed before clinical application can be considered
In utero gene delivery carries some specific procedural risks not encountered in postnatal gene delivery. As for most obstetric interventions, these concern the mother as well as the fetus, and include infection, fetal loss and induction of preterm labour. Other risks, frequently discussed in connection with fetal gene therapy, concern germline transmission, developmental aberrations and the possibility of insertional mutagenesis when using integrating vectors. Transplacental vector spread to the mother is of course also a maternal risk factor for oncogenesis and germline transduction.
Germline transmission. High on the list of possible adverse effects is the risk of an increased danger of germline transmission. As outlined previously, 1 at the proposed gestation times for fetal gene therapy, the germ cells are well compartmentalized in their definitive organs and could thus only be reached from the bloodstream, similar to postnatal life. While the fetal vasculature may be more permeable than in adults, several studies have so far only occasionally detected vector sequences in the gonads of in utero-treated animals. However, this was not associated with detectable transgene expression and vector has, so far, never been found in purified spermatozoa, or in the offspring of these animals in several studies including our own. 14 However, evidence for lentiviral transduction of a subpopulation of gonadal cells isolated by laser capture microdissection was recently observed in female rhesus fetuses after intraperitoneal vector administration. 15 Germline transmission will remain a general point to consider in pre-and postnatal gene therapy. However, as pointed out by Kazazian in 1999, the calculated frequency of naturally occurring endogenous insertional mutations in humans of about one in eight individuals is Developmental aberrations and oncogenesis. The potential of a therapeutic gene product, which is required later in life, to interfere with normal fetal development is so far a hypothetical risk factor. Based on our present knowledge, effects of a transgenic protein on developmental processes are very difficult to predict and can only be detected or ruled out by careful monitoring. As they will be specific for individual proteins and may also depend on the time of gestation, this will have to be examined on a case-by-case basis, and even animal experiments may not reveal all specific potential dangers. An established risk factor of integrating viral vectors is insertional mutagenesis, recently underlined by events after gene therapy with a retroviral vector in very young children treated for X-linked SCID. 16 This risk is also of concern after in utero vector application. The fetal system may be particularly sensitive to such events since integrating vectors prefer to insert their genomes into chromatin in open configuration. Recently, we have observed a very high postnatal incidence of liver tumours in prenatally treated mice after application of an early form of third-generation equine infectious anaemia virus (EIAV) vectors with SIN configuration, but not when using a similar vector with an HIV backbone. 17 Although it is not clear whether insertional mutagenesis has caused this phenomenon, our observations suggest that the fetus may be particularly sensitive to adverse effects associated with this vector system. We are presently elucidating the molecular mechanisms of our findings of oncogenesis in mice and anticipate that this will lead to the design of safer vectors for pre-and postnatal gene therapy for which the mouse fetus appears to provide an excellent highly sensitive test system. An additional safety feature could be provided by ex vivo gene therapy, preferably using autologous fetal stem cells obtained, for example, by fetal liver cell sampling in the first trimester. 18 This approach would allow the use of lower vector doses and prevent vector spread within the fetal, and possibly the maternal organism. It may even allow screening, selection and expansion of transduced cells to avoid those cells with integrations into potential oncogenes before reinfusion. Irrespective of this, these risk factors need to be thoroughly investigated in animal studies by careful monitoring for signs of birth defects following in utero manipulation, and by long-term postnatal follow-up, before clinical application can be considered.
The choice of disease for clinical application requires a high level of certainty that benefit will be provided and that the procedure will not cause additional harm, as termination of pregnancy remains an option to deal with prenatal diagnosed genetic disease
The choice of disease(s) for the first clinical applications of in utero gene therapy requires consideration of disease severity and onset, the ease of targeting and testing for success in utero, as well as evidence for therapeutic efficiency and improved quality of life over conventional therapies (for review see David et al, 2 Waddington et al 19 ). This choice also needs to take into consideration the psychological aspects that may lead a couple faced with the diagnosis of a severe genetic disease to opt for in utero therapy rather than for abortion or to take no action. Although we believe that the demand for such preventive approach does exist, we also realize that only a small proportion of affected families will initially be prepared to take this option even when the procedure is shown in extensive animal experiments to be safe and effective. Therefore, severe but individually very rare conditions such as lysosomal storage diseases are unlikely to be among the first candidates. More likely are relatively frequent genetic diseases where symptomatic treatment can delay disease progression but is unable to cure or prevent premature death. In such cases, parents who would accept and care for an affected child may be prepared to try in utero therapy in particular if a prenatal end point for therapeutic success or failure, which may then allow late abortion, can be built into the protocol. Most likely, such an option would be taken up when an indicator case already exists in the family and a new fetus has been diagnosed prenatally as affected. Of course, the final decision on the choice of disease will also be very much influenced by new developments in fetal gene therapy research, as well as by the progress or failure of postnatal gene therapy for the investigated conditions over the coming years.
Based on our preclinical success, and the possibility for easy monitoring of the transgenic protein, in utero haemophilia B would be an ideal candidate disease. It is well established that early postnatal prophylaxis of this condition is very important but also very expensive, and requires the insertion of central venous catheters, which poses a risk of infection. In addition, development of immune reactions against the therapeutic factor IX is sometimes a major complication. However, as haemophilia is therapeutically manageable and postnatal gene therapy is showing encouraging results, it is unlikely to be accepted as the first disease for clinical application of in utero gene therapy. The successful correction of haemophilia by in utero gene delivery and long-term hepatocyte gene expression, indicates that many genetic diseases that require gene transfer to the liver such as ornithine transcarbamylase deficiency, phenylketonuria and familial hypercholesterolaemia may have a very good chance of success.
Using the relevant mouse disease models, we have also made good progress with lentivirus marker gene transduction of all muscle groups relevant for treatment of Duchenne muscular dystrophy (including the respiratory muscles and the heart 20 ) and to the airway epithelia using first-generation and gutless adenoviruses for cystic fibrosis.
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Central to any ethical considerations of in utero gene therapy is the understanding that termination of pregnancy is a reasonably safe maternal option for dealing with an inherited genetic disease. We see this as the main specific ethical issue in fetal gene therapy. In utero gene therapy will, therefore, need to be highly reliable in preventing the disease, while not causing additional damage. It will, therefore, require even stricter medical indications and safety standards than most postnatal applications, where gene therapy is in most cases the last hope for treatment of an otherwise lethal condition. During the introductory phase of transferring this technology to humans, the involved risks may not be easily ascertained. Particular care will therefore be required regarding informed maternal consent based on detailed counselling and the understanding of risks versus benefits. Another issue concerns the legal and ethical status of the fetus. As pointed out previously 1 by Fletcher and Richter, we would like to emphasize that the 'previable fetus is totally dependent on a pregnant women's autonomous decision for its status in medicine'. This includes the prospective mother's right to abortion, even of a nonaffected fetus, and therefore, the availability of fetal gene therapy should not in any way infringe her autonomy in these decisions.
Our knowledge about attitudes of the general public, and of affected patients and their families, towards fetal gene therapy is presently at best anecdotal. Preparations for clinical in utero gene therapy trials should therefore include a survey of this important aspect among patients and families, health workers and a cross-section of the general public, based on a clear explanation of the aims, possibilities and limitations of the proposed clinical application. This may help to improve information provided, identify and address fears and concerns that this novel approach to gene therapy may cause and provide a scientific basis for the rational assessment of the risks and benefits of in utero gene therapy. We hope that this will lead to the necessary broad support and ethical acceptance required for its eventual clinical application.
Prospects
Although in utero gene therapy has much to offer in terms of prevention of severe genetic disease, its actual application in humans will crucially depend on our ability to demonstrate safety and efficiency as outlined above.
The rapid development of fetal medicine and imaging will continue to increase the ease and safety of vector delivery. In effect, this may well become safer for the mother, than termination of pregnancy or interventions related to preimplantation diagnosis.
As often with new therapeutics, only when they become efficient are potential side effects and hazards observed. This is certainly the case in relation to the observed oncogenic events associated with in utero application of one particular lentivirus vector and it is beneficial that this observation was already made in our animal studies, as it reflects a more general problem of gene therapy vector safety as highlighted by the human SCID trial.
Research towards understanding the mechanisms of these events is presently one of the most intensive research areas in gene therapy and will certainly lead to the design of safer vectors within the next 3-5 years. The fetal mouse system may even emerge as a particularly sensitive test system for such systems. Although the main emphasis will clearly be on the development of genuinely safer vectors, other approaches such as the incorporation of conditional suicide genes into the vector to enable destruction of transduced cells in case of malignancy and ex vivo transduction of autologous (stem) cells to reduce vector spread, as well as combinations of all these approaches, can be expected.
Animal models of severe genetic diseases in the mouse and hopefully, for example, by using transgenic techniques, also in sheep or other larger animals will be urgently needed to demonstrate proof of principle for efficiency and safety in preparation for the first diseases selected for potential in utero gene therapy in humans. These studies will also have to look carefully at the normal levels of expression of the therapeutic protein and exclude any adverse effects by over-expression of the transgenic protein.
Finally, progress in understanding of the human genome will increase the demand for genetic screening programmes and preventive approaches for human genetic disease into which safe, effective in utero gene therapy may be incorporated in the future.
